lunsumio
roche registration gmbh - mosunetuzumab - lymfooma, follicular - antineoplastic agents, monoclonal antibodies - lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (fl) who have received at least two prior systemic therapies.
vabysmo
roche registration gmbh - faricimab - wet macular degeneration; macular edema; diabetes complications - silmätautien - vabysmo is indicated for the treatment of adult patients with:neovascular (wet) age-related macular degeneration (namd),visual impairment due to diabetic macular oedema (dme).
columvi
roche registration gmbh - glofitamab - lymphoma, large b-cell, diffuse - antineoplastiset aineet - columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl), after two or more lines of systemic therapy.
madopar 200 mg / 50 mg tabletti
roche oy - benserazide hydrochloride, levodopa - tabletti - 200 mg / 50 mg - levodopa ja dekarboksylaasin estäjä
roaccutan 10 mg kapseli, pehmeä
roche oy - isotretinoinum - kapseli, pehmeä - 10 mg - isotretinoiini
roaccutan 20 mg kapseli, pehmeä
roche oy - isotretinoinum - kapseli, pehmeä - 20 mg - isotretinoiini
madopar 100 mg / 25 mg tabletti
roche oy - benserazide hydrochloride, levodopa - tabletti - 100 mg / 25 mg - levodopa ja dekarboksylaasin estäjä
pulmozyme 1 mg/ml sumutinliuos
roche oy - dornase alfa - sumutinliuos - 1 mg/ml - dornaasi alfa (desoksyribonukleaasi)
madopar quick 100 mg / 25 mg liukeneva tabletti
roche oy - benserazide hydrochloride, levodopa - liukeneva tabletti - 100 mg / 25 mg - levodopa ja dekarboksylaasin estäjä
roferon-a 3 milj.iu/0.5 ml injektioneste, liuos, esitäytetty ruisku
roche oy - interferonum alfa-2a - injektioneste, liuos, esitäytetty ruisku - 3 milj.iu/0.5 ml - interferoni alfa-2a